Although contradictory findings have been reported on the involvement of NLRP3 inflammasome in the pathogenesis of bronchial asthma [70,71], increasing evidence indicates that NLRP3 inflammasome activation may be one of the pivotal players in CS-resistant asthmatic features in both type 2 and non-type 2 severe asthma. The gene discussed is NLRP3; the disease is asthma.